We are live on ! Find out more
NUVB icon

Nuvation Bio

117 hedge funds and large institutions have $837M invested in Nuvation Bio in 2022 Q1 according to their latest regulatory filings, with 19 funds opening new positions, 37 increasing their positions, 36 reducing their positions, and 7 closing their positions.

New
Increased
Maintained
Reduced
Closed

171% more first-time investments, than exits

New positions opened: 19 | Existing positions closed: 7

11% more funds holding

Funds holding: 105117 (+12)

1.66% more ownership

Funds ownership: 71.35%73.01% (+1.7%)

3% more repeat investments, than reductions

Existing positions increased: 37 | Existing positions reduced: 36

0% more funds holding in top 10

Funds holding in top 10: 44 (0)

37% less capital invested

Capital invested by funds: $1.32B → $837M (-$483M)

Holders
117
Holders Change
+12
Holders Change %
+11.43%
% of All Funds
1.84%
Holding in Top 10
4
Holding in Top 10 Change
Holding in Top 10 Change %
% of All Funds
0.06%
New
19
Increased
37
Reduced
36
Closed
7
Calls
$32K
Puts
Net Calls
+$32K
Net Calls Change
-$215K

NUVB Hedge Fund Activity: Q1 2022 in Review

117 of the 6,360 institutional investors tracked by Wall St. Rank reported a position in Nuvation Bio (NUVB) for Q1 2022, worth a combined $837M — down 37% from $1.32B a quarter earlier.

Buyers outnumbered sellers: 19 funds opened new NUVB positions and 7 closed out — a net gain of 12 holders — while 37 added to existing stakes and 36 trimmed.

The largest buyer was Baupost Group, adding an estimated $10.2M. The largest seller was Avidity Partners Management, cutting an estimated $14.2M.

  • 117 institutional investors held Nuvation Bio (NUVB) as of Q1 2022, up from 105 in Q4 2021.
  • Funds reported $837M of Nuvation Bio stock for Q1 2022, down 37% quarter-over-quarter.
  • 19 funds opened new Nuvation Bio positions in Q1 2022 and 7 closed out, a net change of +12 holders.
  • The largest Nuvation Bio buyer in Q1 2022 was Baupost Group, an estimated $10.2M added.
  • The largest Nuvation Bio seller in Q1 2022 was Avidity Partners Management, an estimated $14.2M sold.

Based on aggregated 13F filings for Q1 2022.